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svery 40 s someone in the U.S. has a stroke, and
every 4 min a patient dies from a stroke. Of the
800,000 strokes a year, close to 200,000 are
recurrent attacks (1). Strokes have a profound
mpact which is even greater in women and minorities
2). National statistics from death certificate data
emonstrate an increase in deaths attributed to stroke
or blacks (3). The BASIC (Brain Attack Surveillance
n Corpus Christi) study demonstrated an increased
ncidence of stroke among Mexican Americans com-
ared with non-Hispanic whites (4). Given the sub-
tantial morbidity, the estimated direct and indirect
ost of stroke for 2010 is $73.7 billion (1). Large-scale
reventive efforts, while ideal, are difficult to imple-
ent and even more difficult to adhere to, and our
bility to minimize the incidence of strokes has been
odest at best. Not surprisingly, there is a great
mount of enthusiasm to identify treatable causes to
revent first and recurrent strokes.
Determining the etiology of a stroke may influence
rognosis, therapy and, very importantly, the likeli-
ood of stroke recurrences. Of all strokes, approxi-
ately 87% are ischemic, and 10% are due to intra-
erebral hemorrhage; about 20% of strokes arise from
he heart and are thought to be, albeit often with a bit
ore optimism than based on high-quality data, best
uited for prevention with interventional technologies
5). Such cardioembolic strokes are generally large and
rone to early recurrence with higher mortality—all of
hich make prevention a more pressing issue. It is
enerally understood that the exact source of the
mbolism must be identified to prevent recurrences
nd thus provide effective therapy. In 10% to 30% of
rom the *Division of Cardiology, VA Medical Center and University ofr
innesota, Minneapolis, Minnesota; and the †University of California,
rvine, California.nstances, the etiology of the stroke is not obvious
espite a detailed work up; this group, termed cryp-
ogenic stroke, represents an unfortunate gap in our
nowledge (6).
In patients without valvular disease, the left atrium
LA) is thought to be involved in a thromboembolic
rocess in 2 ways: either as a source when the clot
rises from the LA appendage, or less frequently, as a
assageway for venous thrombi through a patent
oramen ovale (PFO). With respect to cardioembolic
trokes, the disease process that has justifiably received
he most attention is atrial fibrillation (AF) and the
tructure that has received the most attention is the
A appendage. In nonvalvular AF, LA thrombi
lmost exclusively tend to arise in the LA appendage
nd preventing their access to the systemic circulation,
s with an LA appendage occlusive device, can be
eneficial. The PROTECT AF (WATCHMAN
eft Atrial Appendage System for Embolic Protec-
ion in Patients With Atrial Fibrillation) trial demon-
trated that in the setting of nonvalvular AF, exclud-
ng the LA appendage from the systemic circulation
ith a device was noninferior to anticoagulation ther-
py with warfarin (7). In rheumatic heart disease, the
isk of embolic stroke is much higher, but curiously, an
A thrombus is identified in the appendage in only
ne-half the patients. In the remaining patients, it is
ften located elsewhere in the LA (8). This raises the
ntriguing question—where else can a thrombus arise
n the LA (that might allow us to whittle away the
ryptogenic stroke group) and why does that structure
ost a thromboembolic source?
The possible importance of a pouch-like structure
n the LA side of the interatrial septum was described
ecently in an autopsy study (9). Termed a left atrium
eptal pouch (LASP), this structure was proposed to
epresent an incomplete fusion of the septum primum
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1297nd septum secundum, during closure of foramen
vale. When a foramen ovale closed spontaneously, in
significant number the septum primum and septum
ecundum fused only at the caudal limit of the zone of
verlap. This incomplete fusion resulted in a pouch
hat, in the majority of instances, communicated with
he LA. This kangaroo pouch–like structure was seen
n about one-third of hearts with a depth of 8  4
m. Data from the angiographic computed tomog-
aphy scans has also indicated that the prevalence and
epth of the structure in live patients is similar to that
bserved in autopsy studies (10). It is conceivable that
ncomplete fusion at cranial limit of the zone of
verlap would result in a right atrial septal pouch with
n inferiorly facing mouth.
Two papers in this issue of iJACC provide
ome further data on this entity (11,12). A picto-
ial essay by Gurudevan et al. (11) proposes the
easibility of imaging an atrial pouch with clarity.
t has been tacitly believed that the LA, except
or the appendage, is a smooth structure. The
forementioned autopsy study suggested that in
bout one-third of subjects the LA pouch could
ontribute to stasis, thus fulfilling some elements
f the 1850s concept of the Virchow triad neces-
ary for a thrombus formation. Whether this the-
retical possibility in the LASP was actually asso-
iated with thrombus in the living human being
as still an unclear element. In the current pre-
entation, authors provide 3 examples where the
nswer may be affirmative. Two of 3 examples ap-
ear to have developed a thrombus probably due
o stasis within the LA. Although stasis within
he pouch may have played a role, 1 of the 3 pa-
ients seemed to have developed a thrombus due
o endothelial denudation. The chronic inflamma-
ion seen at the site of attachment of the throm-
us to the atrial septum supported this conten-
ion; history of deep venous thrombosis was also
resent in this patient.
Granted that LASP can play host to a throm-heart disease and stroke statistics—2010
excess burden of str
Stroke 2004;35:426f literature about PFO, there is much to be
earned before one can place such a discovery in
erspective. A possibility cannot be denied that
he LASP could turn out to be a big player in the
tory of cardioembolic strokes arising from the
A. In this issue of iJACC, Tugcu et al. (12),
rovide the first prospective look at stroke due to
ASP and show that the incidence of stroke is
ot significantly influenced by LASP. While the
aper does have a number of limitations, it in-
luded a sizable population and had used reason-
ble imaging technology. This suggests that even
f LASP can cause strokes, it seems from early
ata and the clinical experience of rarely seeing a
lot in the LASP compared to the frequency in
he LA appendage, that it is not likely to have a
aterially large population attributable risk of
ryptogenic strokes.
However, before dismissing this entity into the
ootnotes of medicine or before elevating it into a full
ember of the treatable stroke foci pantheon, we
elieve that this area still needs more robust evalua-
ion. Future investigations will need to focus on 1) the
opulation attributable risk of stroke and embolism
ue to the LASP; and 2) factors affecting the throm-
ogenicity of the pouch. We presented these 2 very
ifferent reports to show the usual ferment of science
hat occurs when a relatively new entity is implicated.
ur discerning readers will surely ponder about what
hapes one’s thinking about literature—the excitement
f an observational hypothesis (how pulmonary vein
ows could influence thrombus formation in a LASP)
n the Gurudevan report (11) with the reality of hard
ata, despite its limitations, from the Tugcu (12)
eport. Such exchanges will finally resolve the role of
he LASP as a possible culprit in embolic strokes and
hether it has the potential to be a viable target for
herapy in cardioembolic strokes, especially those that
ay carry a cryptogenic label. To quote Thomas
efferson, it is laudable to encourage investigation but
us, how often does it lead to a stroke? Like a lot should we not hold back conclusion (13)?E F E R E N C E S
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